Publications by authors named "M McCreery"
Background: Prehospital rapid sequence intubation first pass success rates vary between 59% and 98%. Patient morbidity is associated with repeat intubation attempts. Understanding what influences first pass success can guide improvements in practice.
View Article and Find Full Text PDFObjective: The current study identified and compared different treatment fidelity reporting methods.
Method: This paper includes 2 studies. In Study 1, the researchers compared and contrasted 3 sources of fidelity obtained in a study previously published by the authors; whereas, Study 2 did the same using a structured review of the literature.
Article Synopsis
- LGR4, LGR5, and LGR6 are G-protein-coupled receptors involved in Wnt signaling, but only LGR6 is identified as an epithelial stem cell marker in squamous cell carcinoma (SCC).
- By using advanced mouse models, researchers found that LGR6 is linked to increased stem cell characteristics and higher frequencies in advanced SCCs, while downregulation of LGR6 leads to heightened skin cell proliferation.
- Mice lacking LGR6 show a greater risk for SCC development, suggesting a compensatory role of LGR5, which parallels findings in humans with Wnt pathway gene mutations that increase SCC susceptibility.
Article Synopsis
- Human tumors exhibit significant genetic variability, but the dynamics of how different tumor subclones spread and form metastases are not well understood.
- Researchers conducted whole-exome sequencing on 103 tumor samples from genetically diverse mice to reveal that most metastases emerge simultaneously from the primary tumor, indicating a parallel evolution rather than a linear progression.
- Specific mutations linked to the primary tumors and their metastases highlight the role of factors intrinsic to tumors and genetic variations in determining which tumors spread, offering insights into the clonal evolution of cancer and potential avenues for new therapies.
Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies. Two critical features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target. No prior TKI has demonstrated both of these properties.
View Article and Find Full Text PDF